department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Xcopri · pharmadog

pharmadog
drugs
Xcopri

drug · small molecule

patient view →

cenobamate

Marketedupdated 2mo ago

by SK Life Science Inc🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 3 investigational indications.

targets

Sodium channel alpha subunitGABA-A receptor; anion channel

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Xcopri

trade names

Ontozry, Xcopri

generic

cenobamate

MOA

Sodium channel alpha subunit inhibitor; GABA-A receptor; anion channel positive allosteric modulator

indication

Tonic-Clonic (Grand Mal) Seizure

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 30, 2032

~6.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Jun 16, 2039method-of-use (U-3610)US 11654133
Jun 16, 2039method-of-use (U-3610)US 11654133
Jun 16, 2039method-of-use (U-3610)US 11654133
Jun 16, 2039method-of-use (U-3610)US 11654133
Jun 16, 2039method-of-use (U-3610)US 11654133
Jun 16, 2039method-of-use (U-3610)US 11654133
Oct 30, 2032compositionUS 7598279
Oct 30, 2032compositionUS 7598279
Oct 30, 2032compositionUS 7598279
Oct 30, 2032compositionUS 7598279
Oct 30, 2032compositionUS 7598279
Oct 30, 2032compositionUS 7598279

Trials studying cenobamate

phase3A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Oldsrecruitingn=20
phase3Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizuresactive not recruitingn=140
phase1Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizurescompletedn=26
phase4Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsyactive not recruitingn=49
phase3Cenobamate Open-Label Extension Study for YKP3089C025enrolling by invitationn=145
—Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spainrecruitingn=300
phase3Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizurescompletedn=169
phase3ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.recruitingn=15

more trials →